Sham Mailankody is a medical oncologist and hematologist specializing in the care of people with multiple myeloma and related plasma cell disorders, With his colleagues at Memorial Sloan Kettering Cancer Center, he is focused on identifying optimal treatment strategies for people with these disorders. He is interested in the molecular pathways underlying the progression of plasma cell disorders and the development of targeted strategies aiming to delay, prevent, and cure full-blown disease. He also has an interest in health policy as it relates to oncologic drug approvals and the cost of cancer care.